Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway

Molecular Medicine Reports

Volumn 18, Issue 4, 2018, Pages 3625-3630

  Yao, Di ^a   Wang, Suyu ^a   Wang, Min ^a   Lu, Weiping ^a  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; High mobility group box 1; Sodium glucose co transporter 2 inhibitors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 1; DAPAGLIFLOZIN; FIBRONECTIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; HMGB1 PROTEIN, HUMAN; PROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS; HISTOLOGY; HK-2 [HUMAN KIDNEY] CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY PROXIMAL TUBULE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; HYPERGLYCEMIA; METABOLISM; PHARMACOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZHYDRYL COMPOUNDS; CELL LINE, TUMOR; GLUCOSIDES; HMGB1 PROTEIN; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; KIDNEY TUBULES, PROXIMAL; NF-KAPPA B; OXIDATIVE STRESS; PROTECTIVE AGENTS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85052692606     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2018.9393     Document Type: Article

References (23)

1. Xue R, Gui D, Zheng L, Zhai R, Wang F and Wang N: Mechanistic insight and management of diabetic nephropathy: Recent progress and future perspective. J Diabetes Res 2017: 1839809, 2017.
2. Zhu P, Xie L, Ding HS, Gong Q, Yang J and Yang L: High mobility group box 1 and kidney diseases (Review). Int J Mol Med 31: 763-768, 2013.
3. Kim J, Sohn E, Kim CS, Jo K and Kim JS: The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 33: 524-529, 2011.
4. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
5. Xie J, Méndez JD, Méndez-Valenzuela V and Aguilar-Hernández MM: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 25: 2185-2197, 2013.
6. Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K and Utsunomiya K: SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 18: pii: E1083, 2017.
7. Komala MG, Panchapakesan U, Pollock C and Mather A: Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 22: 113-119, 2013.
8. Moses RG, Colagiuri S and Pollock C: SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 7: 405-415, 2014.
9. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C and Mather A: Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8: e54442, 2013.
10. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
11. Gallagher H and Suckling RJ: Diabetic nephropathy: Where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab 18: 641-647, 2016.
12. Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, et al: Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78: 287-295, 2010.
13. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000.
14. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D and Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994.
15. Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, et al: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51: 3532-3544, 2002.
16. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, et al: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371: 1392-1406, 2014.
17. Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA and Cherney DZ: Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308: F77-F83, 2015.
18. Hovind P, Rossing P, Johnson RJ and Parving HH: Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr 21: 124-127, 2011.
19. Satirapoj B, Supasyndh O, Chaiprasert A, Ruangkanchanasetr P, Kanjanakul I, Phulsuksombuti D, Utainam D and Choovichian P: Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton) 15: 253-258, 2010.
20. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA and Sjöström CD: Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18: 590-597, 2016.
21. Inoguchi T and Nawata H: NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 6: 495-501, 2005.
22. Noronha IL, Niemir Z, Stein H and Waldherr R: Cytokines and growth factors in renal disease. Nephrol Dial Transplant 10: 775-786, 1995.
23. Navarro-González JF and Mora-Fernández C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442, 2008.